H.R. 6973 · 117th Congress
Enhanced Access to Affordable Medicines Act of 2022
- Stage
- In committee
- Sponsor
- Buddy Carter
- Introduced
- 2022-03-08
- Latest action
- 2022-03-09 · Referred to the Subcommittee on Health.
Summary
Enhanced Access to Affordable Medicines Act of 2022
This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.